Abstract:Cancer-associated fibroblasts (CAFs)-mediated metabolic support plays a vital role in tumorigenesis. The metabolic network between cancer cells and CAFs may serve as promising targets for cancer therapy. Here, aiming at targeted blockade of the metabolic support of CAFs to cancer cells, a biomimetic nanocarrier is designed by coating solid lipid nanoparticles containing chemotherapeutic paclitaxel (PTX) and glycolysis inhibitor PFK15 with hybrid membranes of cancer cells and activated fibroblasts. The nanoparticles possess outstanding dual-targeting ability which can simultaneously target cancer cells and CAFs. The encapsulated glycolysis inhibitor PFK15 can prevent the glycolysis of cancer cells and CAFs at the same time, thus increasing the chemosensitivity of cancer cells and blocking the metabolic support of CAFs to cancer cells. The results showed that the combination of PTX and PFK15 exhibited synergistic effects and inhibited tumor growth effectively. Moreover, the biomimetic nanoparticles obviously reduced the lactate production in the tumor microenvironment, leading to activated immune responses and enhanced tumor suppression. This work presents a facile strategy to destroy the metabolic network between cancer cells and CAFs, and proves the potential to elevate chemo-immunotherapy by glycolysis inhibition. STATEMENT OF SIGNIFICANCE: In many solid tumors, most cancer cells produce energy and carry out biosynthesis through glycolysis, even in aerobic conditions. As the main tumor stromal cells, cancer-associated fibroblasts (CAFs) usually turn oxidative phosphorylation into aerobic glycolysis with metabolic reprogramming and provide high-energy glycolytic metabolites for cancer cells. The metabolic network between cancer cells and CAFs is regarded as the vulnerability among cancer cells. Moreover, lactate produced by cancer cells and CAFs through glycolysis often leads to the immunosuppressive tumor microenvironment. The present study provides an effective approach to destroy the metabolic network between cancer cells and CAFs and greatly improves the antitumor immune response by reducing lactate production, which serves as a promising strategy for combined chemo-immunotherapy mediated by glycolysis.

In Situ Engineering Cancer Mask to Immobilize Tumor Cells and Block Metastasis

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Transformable Nanomaterials As an Artificial Extracellular Matrix for Inhibiting Tumor Invasion and Metastasis

Genetically Engineered Membrane-Based Nanoengagers for Immunotherapy of Pancreatic Cancer

Self-Assembled Core-Shell Nanoscale Coordination Polymer Nanoparticles Carrying a Sialyltransferase Inhibitor for Cancer Metastasis Inhibition

Specifically Editing Cancer Sialoglycans for Enhanced Immunotherapy In Vivo through Aptamer‐Enzyme Chimeras

Glycopolymer Engineering of the Cell Surface Changes the Single Cell Migratory Direction and Inhibits the Collective Migration of Cancer Cells

Dynamic Display of Cell Targeting Motifs via Natural Glycopeptide Recognition for Cancer Cell Isolation

Functional bionanomaterials for cell surface engineering in cancer immunotherapy

Wrecking neutrophil extracellular traps and antagonizing cancer-associated neurotransmitters by interpenetrating network hydrogels prevent postsurgical cancer relapse and metastases

Cancer Immunotherapy Based on Cell Membrane-Coated Nanocomposites Augmenting Cgas/sting Activation by Efferocytosis Blockade

Trident Molecule with Nanobrush-Nanoparticle-Nanofiber Transition Property Spatially Suppresses Tumor Metastasis.

In Situ Modification of the Tumor Cell Surface with Immunomodulating Nanoparticles for Effective Suppression of Tumor Growth in Mice

Abstract IA010: Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans

Metabolic Reprogramming by Dual-Targeting Biomimetic Nanoparticles for Enhanced Tumor Chemo-Immunotherapy

In-situ nanoplatform with synergistic neutrophil intervention and chemotherapy to prevent postoperative tumor recurrence and metastasis

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

Biomimetic O2 Self-generated Hybrid Membrane Nanoplatform for Blocking the Polarization Towards Immunosuppressive M2 Macrophage Phenotype and Enhancing Sonodynamics Therapy in Orthotopic Colorectal Cancer

Sialic Acids Blockade‐Based Chemo‐Immunotherapy Featuring Cancer Cell Chemosensitivity and Antitumor Immune Response Synergies